Key clinical point: Dapagliflozin is particularly effective in reducing major adverse cardiovascular events in the subset of type 2 diabetics with prior MI.
Major finding: The absolute risk reduction in MACE with dapagliflozin versus placebo was 2.6% over a median of 4.2 years.
Study details: This subanalysis of the 17,160-patient randomized DECLARE-TIMI 58 trial focused on the 3,584 participants with type 2 diabetes and prior MI.
Disclosures: DECLARE-TIMI 58 was funded by AstraZeneca. The presenter serves as a consultant to the company.
REPORTING FROM ACC 19